Lexicon Pharmaceuticals (LXRX) R&D Day 2025 summary

Pipeline overview and program updates

• LX9211 (pilivapadin) is a novel, non-opioid, once-daily oral therapy for neuropathic pain, advancing toward a phase IIb data readout in DPNP (diabetic peripheral neuropathic pain) this quarter.

• The PROGRESS phase IIb trial completed enrollment ahead of schedule, exceeding targets by 20%, reflecting high unmet need and strong patient/site interest.

• The clinical program includes prior phase IIa studies in DPNP and postherpetic neuralgia, both showing proof of concept and informing current trial design.

• Pilavapadin, a new oral, once-daily, non-opioid agent, demonstrated clinically and statistically significant pain reduction and broad potential across neuropathic pain types.

Neuropathic pain landscape and unmet needs

• Neuropathic pain affects millions, with only 30% achieving partial pain management and significant impacts on quality of life, including mobility loss, depression, and sleep disruption.

• DPNP is highly prevalent, with approximately 9 million diagnosed in 2024 and projected to reach 13 million by 2035.

• Current treatments are limited, with little innovation in the past 20 years and a high rate of therapy switching or add-on due to inadequate control.

Clinical trial data and development milestones

• RELIEF-DPN-1 phase IIa showed statistically significant pain reduction in the low-dose arm versus placebo, with robust secondary endpoint improvements (sleep, worst pain, least pain).

• The PROGRESS phase IIb study for LX9211 in DPNP completed enrollment of 496 patients, with top-line data expected soon and phase III initiation targeted for 2025.

• RELIEF-PHN-1 achieved proof of concept in postherpetic neuralgia, though statistical significance was not reached.

• The PROGRESS phase IIb trial uses a patient-centric design, placebo control, stratification for background therapy, and improved tolerability by removing the loading dose.

• Enrollment in PROGRESS was completed a quarter early, with top-line results expected this quarter and phase III initiation targeted for 2025.